Mainz Biomed N.V. announced the enrollment of the first patient in its eAArly DETECT 2 feasibility study, which evaluates the company’s next-generation colorectal cancer (CRC) test. This milestone signifies the formal commencement of the study after months of preparatory work.
The study aims to enroll approximately 2,000 average-risk patients to validate previous industry-leading results in detecting advanced precancerous lesions (APL) and early-stage CRC. Top-line results are targeted for the fourth quarter of 2025.
This clinical trial is a crucial step in advancing Mainz Biomed’s mission to transform CRC screening to CRC prevention. The outcome of eAArly DETECT 2 will inform the final protocols for ReconAAsense, the company’s U.S. pivotal study, which is on track to initiate in 2026.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.